金達威(002626.SZ):子公司擬出資165萬元投設合資公司
格隆匯12月28日丨金達威(002626.SZ)公佈,為了不斷拓展和把握中國營養健康領域的潛在需求和市場機會,打造市場爆款產品,公司全資子公司迪諾寶(廈門)國際貿易有限公司(“迪諾寶”)與廣州南沙通用網絡有限公司(“通用網絡”)通過友好協商,於2021年12月28日簽署《合資協議》,同意共同投資設立上海金葱歲月生物科技有限公司(最終以市場監督管理部門核准的名稱為準)(“合資公司”)。
合資公司註冊資本人民幣300萬元。迪諾寶以現金出資人民幣165萬元,擁有合資公司55%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.